Compare AbCellera Biologics Inc (ABCL) vs Crowdstrike Holdings Inc (CRWD) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

CrowdStrike (CRWD) trades at $194.62, up 0.43% today, with a strong technical outlook showing bullish momentum and key resistance at $199. The stock recently completed a 4-for-1 split, enhancing accessibility. Revenue growth accelerated to 26% year-over-year in Q1 2026, with EPS consistently beating estimates, though net margins remain negative. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $180.33 consensus target, despite premium valuations like a P/E of 765.

Outlook remains optimistic due to robust cybersecurity demand and AI-driven threats, but high valuation and profitability challenges pose risks. Investors should weigh growth potential against elevated multiples and competitive pressures in the sector.